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Abstract The free radicals nitric oxide (.NO) and superoxide 
(O~) are known to react to form peroxynitrite (ONOO-), a highly 
reactive species. Peroxynitrite has been suggested to play an 
important role in the cellular damage associated with the overpro- 
duction of" NO, but there are very limited data regarding its in 
vivo formation. Here we demonstrate that injection of endotoxin 
into rats leads to the expression of an inducible isoform of -NO 
synthase (iNOS) in the thoracic aorta at 6 h and an increase in 
the circulating levels of nitrite/nitrate. Moreover, at the same 
time point, there is a marked increase in the immunoreactivity of 
nitrotyrosine, a marker of peroxynitrite in the aorta. The forma- 
tion of nitrotyrosine was prevented by inhibiting the activity of 
NOS by NC-methyI-L-arginine in vivo. Our data suggest that 
during endotoxin shock, part of "NO, produced following the 
induction of iNOS, is converted into peroxynitrite in the vicinity 
of large blood vessels. The demonstration of the in vivo formation 
of peroxynitrite at sites of • NO overproduction may necessitate 
the development of novel and additional approaches for limiting 
or preventing" NO-related cytotoxic or vasodilatory actions dur- 
ing circulatory shock. 
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mediated by peroxynitrite [9]. The formation of peroxynitrite 
has been proposed in a number of pathophysiological condi- 
tions that are associated with overproduction of NO and/or 
superoxide. Here we investigate the possibility that the induc- 
tion of iNOS in the aorta during endotoxemia leads to the 
formation of peroxynitrite in the same tissue. 
2. Materials and methods 
2.1. Materials 
Bacterial lipopolysaccharide (E. coli, serotype no. 0127:B8), calmod- 
ulin, NADPH, Na-methyl-L-arginine monoacetate and Dowex 50W 
anion exchange resin were obtained from Sigma (St. Louis, MO). 
L-[2,3,4,5-3H]arginine hydrochloride was obtained from Amersham 
(Arlington Heights, IL). 
2.2. Animals 
Male Wistar rats were obtained from Charles River Laboratories 
(Wilmington, MA). Rats were injected with vehicle, vehicle and the 
NOS inhibitor NC-methyl-L-arginine (15 mg/kg i.p. at 2 h after the 
injection of vehicle), with E. coli endotoxin (10 mg/kg i.p.) or with 
endotoxin and NO-methyl-L-arginine (15 mg/kg i.p. at 2 h after the 
injection of endotoxin). At 6 h, animals were anesthetized with enflu- 
rane and blood was taken by cardiac puncture. After exsanguination, 
thoracic aortae were quickly removed and placed in tissue fixative for 
immunohistochemistry, or into liquid nitrogen for the measurement of 
nitric oxide synthase activity. 
I. Introduction 
The production of large amounts of nitric oxide (. NO) by the 
inducible isoform of" NO synthase (iNOS), in response to pro- 
inflammatory cytokines or endotoxin (bacterial ipopolysac- 
charide, LPS), has been implicated in the suppression of cellular 
respiration and in the pathophysiology of cell and organ dam- 
age associated with circulatory shock [1-3]. During circulatory 
shock, the vascular smooth muscle is a key site of" NO overpro- 
duction, leading to reduced responsiveness to vasoconstrictor 
agents and a progressive dilatation of the vasculature (vascular 
decompensation) [1-3]. 
NO is known to react with superoxide anion (02-) to form 
an even more toxic species, peroxynitrite (ONOO-) [4,5]. The 
formation of peroxynitrite has been demonstrated from acti- 
vated macrophages [6] endothelial cells [7] and human neutro- 
phils [8]. Peroxynitrite is a highly reactive species capable of 
oxidizing many organic molecules [5]. We have previously 
shown that a major product from the spontaneous reaction of 
peroxynitrite with proteins is the formation of nitrotyrosine 
and that nitrotyrosine r presents a specific protein modification 
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2.3. Nitric oxide synthase assay 
Aortae were placed into a homogenation buffer composed of: 50 mM 
Tris-HC1, 0.1 mM EDTA, 0.1 mM EGTA and 1 mM phenylmethylsul- 
fonyl fluoride (pH 7.4). Tissues were then homogenized in the buffer 
on ice using a Tissue Tearor 985-370 homogenizer (Biospec Products, 
Racine, WI). Conversion of [3H]L-arginine to[3H]L-citrulline was meas- 
ured in the homogenates as described [10]. Briefly, cell homogenate (30 
pl) was incubated inthe presence of [3H]L-arginine (10pM, 5 kBq/tube), 
NADPH (1 mM), calmodulin (30 nM), tetrahydrobiopterin (5 gM) and 
calcium (2 mM) for 30 min at 22°C. Reactions were stopped by dilution 
with 0.5 ml of ice-cold HEPES buffer (pH 5.5) containing EGTA (2 
mM) and EDTA (2 mM). Experiments performed in the absence of 
NADPH determined the extent of [3H]L-citrulline formation independ- 
ent of a specific NOS activity. Experiments inthe presence of NADPH, 
without calcium and with EGTA (5 mM), determined the calcium- 
independent (i.e. induced) NOS activity. Reaction mixtures were ap- 
plied to Dowex 50W (Na ÷ form) columns and the eluted [3H]L-citrulline 
activity was measured by a Wallac scintillation counter (Wallac, Gaith- 
ersburg, MD). 
2.4. Nitrotyrosine immunoh&tochemistry 
Aortae were fixed for 3 h in 4% paraformaldehyde and cryoprotected 
by 1 h incubation in 10%, 20% and 30% sucrose in 0.1 M sodium 
cacodylate buffer. The tissues were placed on OTC-coated tissue-hold- 
ers covered with a thin layer of OTC and frozen with distilled Freon 
22 in liquid nitrogen. Eight pm thin sections were placed onto slides and 
stained with the anti-nitrotyrosine antibody. The blocking solution 
consisted of 4% fatty acid free BSA, 10% goat serum and 3% Triton 
X-100 in 0.1 M phosphate buffered saline (PBS), pH 7.2. Samples were 
incubated with either anti-nitrotyrosine polyclonal antibody at 2 pg/ml 
for 3 h, or antigen-competed primary antibody. The antigen-competed 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
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antibody was prepared by diluting the primary antibody at 2 pg/ml in 
10 mM nitrotyrosine (Aldrich) in 0.1 M PBS, pH 7.4. The antibody 
binding on tissue sections was visualized by 1 h incubation with an 
anti-rabbit IgG conjugated toTexas red (1:100 dilution in PBS). Slides 
were examined under a Nikon Diaphot-TND epifluorescence inverted 
microscope. All pictures were obtained under the same magnification 
(25 x lens), camera nd printing settings. 
2.5. Measurement of plasma nitrite~nitrate 
Plasma was ultrafiltrated using 10,000 molecular weight cut-off ul- 
trafiltration units (Fisher Scientific). The nitrate in the deprotinized 
filtrate was reduced to nitrite using E. coli as described previously [11] 
and nitrite was measured by the Griess reaction. The levels of nitrite/ 
nitrate in control male Wistar rats was similar to the values reported 
previously for control male Fischer ats [12]. 
2.6. Statistical evaluation 
All values in the figures and text are expressed as mean + S.E.M. of 
n observations. Student's unpaired t-test was used to compare means 
between groups. A P-value less than 0.05 was considered to be statisti- 
cally significant. 
3. Results 
In control rats, there was detectable calcium-dependent (con- 
stitutive, endothelial type) NOS activity, and no calcium-inde- 
pendent (inducible) NOS activity in the aorta. At 6 h after 
endotoxemia, there was a significant (P < 0.01), more than 4- 
fold increase in the total NOS activity in the aorta, approxi- 
mately half of which was calcium-independent (i ducible) (Fig. 
1). The activity of NOS (both in the aortae of control and in 
endotoxemic rats) could largely be inhibited by N%methyl-L- 
arginine (3 raM) in vitro (Fig. 1). The increase in • NO produc- 
tion in response to endotoxin was also reflected by a 20-fold 
increase in plasma levels of nitrite and nitrate, degradation 
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Fig. 1. Total (black columns) and calcium-independent (i ducible, 
hatched columns) nitric oxide synthase activity in the aorta of vehicle- 
treated control rats and in the aorta of rats at 6 h after E. coli lipopol- 
ysaccharide (10 mg/kg i.p.) (n=3-4). Data are expressed as 
means + S.E.M. of n observations. Grey columns represent total NOS 
activities in the presence of the NOS inhibitor NG-methyl-arginine (3 
mM). **Represents significant difference between the respective NOS 
activities in control animals vs. in rats treated with endotoxin 
(P < 0.01). **Represents significant inhibition of NOS activity by N ~- 
methyl-arginine i  vitro (P < 0.01). 
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Fig. 2. Plasma nitrite/nitrate levels in control animals, in animals at 6 h 
after E. coil lipopolysaccharide (10 mg/kg i.p.) treatment and in animals 
treated with endotoxin and the NOS inhibitor NG-methyl - arginine (15 
mg/kg i.p. at 2 h after the injection of endotoxin). **Represents signif- 
icant increases in nitrite/nitrate plasma levels in rats treated with en- 
dotoxin (with or without N~-methyl-arginine treatment) when com- 
pared to control animals (P < 0.01). tRepresents significant reduction 
by N~-methyl-arginine i  plasma nitrite/nitrate levels in rats treated 
with endotoxin (P < 0.05). 
products of" NO (Fig. 2). This increase was significantly inhib- 
ited by NG-methyl-L-arginine tr atment in vivo (Fig. 2). 
In the aortae of control rats, very low nitrotyrosine im- 
munoreactivity could be observed (Fig. 3a). Similarly, low ni- 
trotyrosine immunoreactivity could be observed in the aortae 
of N~-methyl-L-arginine control rats. In contrast, there was a 
marked increase in the nitrotyrosine immunoreactivity in the 
aortic tissues obtained from rats injected with endotoxin, (Fig. 
3b), which was almost completely absent in the aortae of septic 
animals that received treatment with NG-methyl-L-arginine 
(Fig. 3c). The development of nitrotyrosine immunoreactivity 
in the aortae of septic rats could also be inhibited by competi- 
tion by excess nitrotyrosine during the incubation with the 
nitrotyrosine antibody (Fig. 3d). 
4. Discuss ion 
Using the measurement of tyrosine nitration, a specific 
marker of the presence of peroxynitrite [9,13-16], here we have 
demonstrated that endotoxemia leads to a substantial increase 
in the levels of biologically active peroxynitrite in the vicinity 
of large blood vessels, such as the thoracic aorta. Considering 
that there was a diffuse immunoreactivity throughout the whole 
tissue and that in the vascular smooth muscle, a substantial 
increase in the calcium-independent (i ducible) NOS activity 
could be demonstrated, we assume that mainly iNOS, induced 
in the vascular tissue, is the source of 'NO. The source of 
superoxide may be the vasculature itself and/or activated neu- 
trophil granulocytes. Using N%methyl-L-arginine, we have 
also demonstrated that the nitrotyrosine immunoreactivity (i.e. 
the formation of peroxynitrite), can be prevented by inhibition 
of - NO biosynthesis. 
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Fig. 3. Representative nitrotyrosine immunofluorescence photomicrographs of rat thoracic aortae. (a) Control rats; (b) rats injected with endotoxin; 
(c) rats injected with endotoxin combined with NC-methyl-L-arginine; (d) immunoreactivity in the aortae of septic rats where antibody binding was 
inhibited by excess nitrotyrosine during the incubation period. Similar esults were observed in four different aortae in each experimental group. 
Increased nitrotyrosine l vels have been detected in human 
diseases associated with of oxidative stress; in atherosclerotic 
plaques of human coronary vessels [13], in the lungs of infants 
with acute lung injury and ARDS [14,15], and in synovial fluid 
and plasma from patients with rheumatoid arthritis [16]. En- 
dotoxin-mediated induction of hepatic .NO increased per- 
oxynitrite formation and injury during reperfusion of ischemic 
rat liver [17]. Moreover, an increase in nitrotyrosine im- 
munoreactivity was recently found in the lung of rats injected 
with bacterial endotoxin [18]. It is noteworthy in this contest 
that among many organs tudied, the lung expresses the highest 
specific activity of iNOS in response to endotoxin injection in 
the rat [10]. Thus, it appears that endotoxin shock results in 
induction of iNOS, with subsequent formation of peroxynitrite. 
Based on the protective ffect of inhibitors of NOS in various 
animal models of shock, it is generally assumed that .NO, 
per se, is the active vasodilator and cytotoxic molecule in endo- 
toxemia [1-3]. The present data, however, suggest that endotox- 
emia is associated with the formation of large amounts 
of peroxynitrite in the vicinity of the vasculature. If peroxy- 
nitrite is formed from iNOS-derived •NO in vivo, this would 
necessitate he introduction of different herapeutic strategies 
in order to ameliorate cytotoxic actions. It is noteworthy 
that peroxynitrite also has marked vasodilator properties, and 
its vascular actions are substantially different from that of 
• NO [19,20]. 
In conclusion, we have provided indirect evidence for the 
in vivo formation of peroxynitrite in the vascular smooth 
muscle, a pertinent site o f .NO overproduction i  endotoxae- 
mia. The realization of the formation of peroxynitrite dur- 
ing sepsis at sites o f .  NO overproduction may open ways 
of developing novel, additional approaches for limiting or 
preventing -NO-related cytotoxic or vasodilatory ac- 
tions during circulatory shock and other pathophysiological 
states. 
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